Costamare Inc. (CMRE) Analysts See $0.17 EPS; Neurocrine Biosciences (NBIX) Sentiment Is 1.66

January 14, 2018 - By Louis Casey

Analysts expect Costamare Inc. (NYSE:CMRE) to report $0.17 EPS on January, 25.They anticipate $0.11 EPS change or 39.29% from last quarter’s $0.28 EPS. CMRE’s profit would be $18.17 million giving it 9.35 P/E if the $0.17 EPS is correct. After having $0.16 EPS previously, Costamare Inc.’s analysts see 6.25% EPS growth. The stock increased 0.16% or $0.01 during the last trading session, reaching $6.36. About 440,985 shares traded. Costamare Inc. (NYSE:CMRE) has declined 13.83% since January 14, 2017 and is downtrending. It has underperformed by 30.53% the S&P500.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $7.20 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Costamare Inc. owns and charters containerships to liner companies worldwide. The company has market cap of $679.79 million. As of March 10, 2017, it had a fleet of 69 containerships with a total capacity of approximately 456,000 twenty foot equivalent unit , including 64 vessels in the water, aggregating approximately 415,000 TEU; and 5 newbuild vessels aggregating approximately 41,000 TEU. It has a 15.67 P/E ratio.

Among 6 analysts covering Costamare (NYSE:CMRE), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Costamare had 13 analyst reports since December 18, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Credit Suisse given on Monday, January 30. On Monday, May 1 the stock rating was upgraded by Credit Suisse to “Neutral”. On Wednesday, October 25 the stock rating was maintained by Credit Suisse with “Neutral”. The stock of Costamare Inc. (NYSE:CMRE) has “Equal-Weight” rating given on Thursday, June 30 by Morgan Stanley. The stock of Costamare Inc. (NYSE:CMRE) has “Underweight” rating given on Friday, December 18 by JP Morgan. The stock of Costamare Inc. (NYSE:CMRE) has “Neutral” rating given on Friday, January 29 by Credit Suisse. Barclays Capital reinitiated Costamare Inc. (NYSE:CMRE) on Monday, January 11 with “Equal Weight” rating. The stock of Costamare Inc. (NYSE:CMRE) earned “Overweight” rating by JP Morgan on Wednesday, October 5. The rating was maintained by Stifel Nicolaus on Thursday, May 25 with “Hold”. The stock of Costamare Inc. (NYSE:CMRE) earned “Overweight” rating by Morgan Stanley on Wednesday, February 1.

The stock increased 3.00% or $2.37 during the last trading session, reaching $81.37. About 895,546 shares traded. Neurocrine Biosciences, Inc. (NBIX) has risen 12.51% since January 14, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on February, 13. They expect $-0.03 earnings per share, up 94.12% or $0.48 from last year’s $-0.51 per share. After $-0.13 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -76.92% EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 11 selling transactions for $10.34 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: